Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Polio-Haemophilus Influenzae type b Conjugate Combined Vaccine Biological Page (DTaP-IPV-Hib-HB)

Similar documents
Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Polio-Haemophilus Influenzae type b Conjugate Combined Vaccine Biological Page (DTaP-IPV-Hib-HB)

Diphtheria-Tetanus-Acellular Pertussis Combined Vaccine Biological Page (dtap)

Hepatitis B Vaccine Biological Page

BOOSTRIX -POLIO: Diphtheria-Tetanus- Acellular Pertussis-Polio Combined Vaccine Biological Page (dtap-ipv)

Diphtheria-Tetanus-Acellular Pertussis-Polio- Combined Vaccine Biological Page (DTaP-IPV)

Health Screening Record: Entry Level Due: August 1st MWF 150 Entry Year

Diphtheria-Tetanus-Acellular Pertussis-Polio- Haemophilus influenzae type b Conjugate Combined Vaccine Biological Page (DTaP-IPV-Hib)

Childhood Immunization Status (NQF 0038)

Childhood Immunization Status (NQF 0038)

Pediatric and adolescent preventive care and HEDIS *

Section IA-Introduction

Vaccine Information Statement: PNEUMOCOCCAL CONJUGATE VACCINE

Medical Student Immunization Requirements

Vaccine Information Statement: LIVE INTRANASAL INFLUENZA VACCINE

Tetanus Prevention, Prophylaxis and Wound/Injury Management Standard

Provider Information: Influenza VISs

PART III: CONSUMER INFORMATION

Tick fever is a cattle disease caused by any one of the following blood parasites:

Immunisation and Disease Prevention Policy

PACKAGE LEAFLET: INFORMATION FOR THE USER

Polio Vaccine Biological Page

Methadone Maintenance Treatment for Opioid Dependence

ENA Topic Brief. Adult Immunizations. Key Information

Package leaflet: Information for the user. Dacepton 5 mg/ml Solution for infusion Apomorphine hydrochloride hemihydrate

Dear Student, IMMUNIZATION RECORD INSTRUCTIONS

HPV VACCINATION IN SANDYFORD SERVICES

Implementation of G6PD testing and radical cure in P. vivax endemic countries: considerations

Annex III. Amendments to relevant sections of the Product Information

Table of Contents. 1.0 INFANRIX hexa VACCINE...3

CDC Influenza Division Key Points November 7, 2014

Safety of HPV vaccination: A FIGO STATEMENT

Flu Season Key Points ( )

Immunization for Special Populations

Pneumococcal 13-valent Conjugate Vaccine Biological Page

The estimator, X, is unbiased and, if one assumes that the variance of X7 is constant from week to week, then the variance of X7 is given by

Intravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion

Widening of funding restrictions for rituximab and eltrombopag

GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH

Breast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)

Original Policy Date 12:2013

MEDICATION GUIDE LEMTRADA (lem-tra-da) (alemtuzumab) Injection for intravenous infusion

Action plan: serialisation of Nordic packages focus on Product Codes

Related Policies None

Policy Guidelines: Genetic Testing for Carrier Screening and Reproductive Planning

Infection Control Guidelines for Cabin Crew Members on Commercial Aircraft

Human papillomavirus (HPV) refers to a group of more than 150 related viruses.

Washington University Physician Network Campus Box Duncan Ave, Ste. 301 St. Louis, MO Phone: (314)

Use of Infanrix -IPV+Hib in the infant primary immunisation schedule

CLINICAL MEDICAL POLICY

Dear University of Chicago Student,

CDC Influenza Division Key Points MMWR Updates February 20, 2014

Commissioning Policy: South Warwickshire CCG (SWCCG)

Intravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion

CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION

Triumeq (abacavir, dolutegravir and lamivudine) Product Backgrounder for US Media

Iowa Early Periodic Screening, Diagnosis and Treatment Care for Kids Program Provider Training

Influenza (Flu) Fact Sheet

DRAFT Policy for the Management of Ear Wax

MEDICATION GUIDE Pioglitazone and Metformin Hydrochloride (PYE o GLI ta zone and met FOR min HYE-droe- KLOR-ide)Tablets, USP

Frequently asked questions: Influenza A (H1N1)v

INSTRUCTIONS FOR USE ZINBRYTA (zin-bry-tuh) (daclizumab) Injection, for Subcutaneous Use Single-Dose Prefilled Syringe 150 mg

Request for Prior Authorization for Click here to enter text. Website Form Submit request via: Fax

Completing the NPA online Patient Safety Incident Report form: 2016

MEDICATION GUIDE. (fingolimod) capsules

Package leaflet: Information for the user. Fragmin Graduated Syringe 10,000 IU/ml Solution for Injection dalteparin sodium

Bariatric Surgery FAQs for Employees in the GRMC Group Health Plan

PATIENT INFORMATION. effective for the treatment of the flu in people with long-time (chronic) heart problems or breathing problems.

FDA Dietary Supplement cgmp

Fee Schedule - Home Health Care- 2015

cerliponase alfa (Brineura )

ALCAT FREQUENTLY ASKED QUESTIONS

2017 CMS Web Interface

77 WHO/IPA workshop on Immunisation

Obesity/Morbid Obesity/BMI

MEDICATION GUIDE. (Interferon alfa-2b)

MEDICATION GUIDE Pioglitazone (pie-oh-glit-ah-zohn) and Metformin (met-fore-min) Hydrochloride Tablets USP

Benepali (etanercept): Brief training on additional Risk Minimisation Measures

MEDICATION GUIDE. (canagliflozin) Tablets

DATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 2016 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS

SECTION O. MEDICATIONS

Hepatitis B Immune Globulin Biological Page

Immunization Competencies Education Program

You may have a higher risk of bleeding if you take warfarin sodium tablets and:

Package leaflet: Information for the user. Fragmin 10,000 IU/1 ml and 10,000 IU/4 ml Solution for injection dalteparin sodium

Yescarta (axicabtagene ciloleucel) (Intravenous)

SUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES. ANTI-OBESITY AGENTS Generic Brand HICL GCN Exception/Other QSYMIA 32515, 32744, 32746, 32745

CDC Influenza Technical Key Points February 15, 2018

2017 Optum, Inc. All rights reserved BH1124_112017

This information shows what new challenges are likely to require prevention efforts moving forward.

Key Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red.

Drug Therapy Guidelines

Little Angels Schoolhouse

PACKAGE LEAFLET INFORMATION FOR THE PATIENT

MEDICATION GUIDE REVLIMID (rev-li-mid) (lenalidomide) capsules What is the most important information I should know about REVLIMID?

Rate Lock Policy. Contents

Section V: Immunization

Section 6 Students School District No. 71 (Comox Valley)

The data refer to persons aged between 15 and 54.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

Medication Guide SIGNIFOR [sig-na-for] (pasireotide) Injection

Transcription:

Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Pli-Haemphilus Influenzae type b Cnjugate Cmbined Vaccine Bilgical Page (DTaP-IPV-Hib-HB) Sectin 7: Bilgical Prduct Infrmatin Standard #: 07.214 Created by: Prvince-wide Immunizatin Prgram Standards and Quality Apprved by: Prvince-wide Immunizatin Prgram Standards and Quality Apprval Date: September 1, 2016 Revised: February 15, 2018 Manufacturer Bilgical Classificatin Indicatins fr Prvincially Funded Vaccine Nte: Fr questins related t Travel and r Fr Sale vaccine refer t AHS Travel Health and Cntracted Immunizatin Services resurces. Serlgy GlaxSmithKline Inc. Inactivated Primary immunizatin fr children tw mnths up t and including 23 mnths f age when diphtheria, tetanus, acellular pertussis, pli, Hib and hepatitis B vaccines are indicated fr nn-hyprespnsive individuals. Nte: Hepatitis B vaccine indicated fr: Infants brn t hepatitis B infected mthers r whse primary caregiver is hepatitis B infected (acute cases r carriers) Infants brn March 1, 2018 r later Infants wh are husehld cntacts f a hepatitis B carrier Infants whse families have immigrated t Canada frm areas where there is a high prevalence (8% r higher) f hepatitis B. See Hepatitis B Endemic Cuntries List Primary series fr high risk infants wh have received HBIG and/r hepatitis B vaccine at birth. Exceptin: D nt administer INFANRIX hexa t high risk infants weighing less than 2000g wh received Hepatitis B vaccine and/r HBIG at birth. These infants shuld cntinue t receive the separate Hepatitis B vaccine accrding t the schedule utlined in the Hepatitis B Vaccine Bilgical Page (#07.234). Nte: INFANRIX hexa cntains nly a regular strength dse f Hepatitis B Vaccine and is nt indicated fr infants and children requiring a duble dse f Hepatitis B vaccine. Pre-Immunizatin and Pst immunizatin There are n serlgical tests available fr pertussis, pli r Haemphilus influenza type b. Serlgical testing is nt typically recmmended t assess levels f immunity t diphtheria r tetanus. Fr additinal infrmatin see the Alberta Health DAT/TAT Interpretatin tables at: https://pen.alberta.ca/dataset/715eb289-53b2-4c69-a17e- 60717b9e6eb8/resurce/f91417df-26c0-435f-b3da- fea0b031617a/dwnlad/aip-adverse-events-fllwing-immunizatin-dat- TAT-Levels.pdf Hepatitis B see Bilgical Page 07.234 Hepatitis B Vaccine fr interpretatin f serlgy. Immunizatin Prgram Standards Manual Page 1 f 5 Ppulatin, Public and Indigenus Health

Schedule Children 2 mnths up t and including 23 mnths f age: Dse 1: 2 mnths f age Dse 2: 4 mnths f age Dse 3: 6 mnths f age Ntes: Third dse shuld nt be given t infants befre 6 mnths (24 weeks r 168 days) f age. Spacing recmmendatin fr ff schedule children is 2 mnths (8 weeks) between dses hwever, minimum intervals respecting all f the fllwing may be used: Minimum f 4 weeks between the first and secnd dse AND, Minimum f 8 weeks between the secnd and third dse AND Minimum f 4 mnths (16 weeks r 112 days) between the first and third dse. Where a dse f hepatitis B vaccine is given at birth, INFANRIX hexa can be used fr the subsequent dses as per the schedule indicated abve. An infant in this case wuld receive a ttal f 4 dses f hepatitis B vaccine. Where a dse f hepatitis B vaccine is given at birth, INFANRIX hexa can be used fr the secnd dse frm the age f six weeks. This spacing wuld nly be used if early immunizatin is required due t increased risk f expsure t antigens ther than Hepatitis B cntained in the vaccine. The first three dses f an immunizatin series shuld be cmpleted with the same cmbinatin prduct whenever pssible. If this is nt pssible an alternative cmbinatin may be used. Ideally a series started with INFANRIX hexa will be cmpleted with INFANRIX hexa. A series started with separate DTaP-IPV-Hib and Hepatitis B vaccine shuld be cmpleted with the separate vaccines. Exceptin as detailed abve is infants given a dse f hepatitis B vaccine at birth. The schedule and spacing cnsideratins fr this vaccine vary slightly frm thse f the individual HBV and DTaP-IPV-Hib vaccines. Ensure the apprpriate schedule is fllwed fr the vaccine(s) that are being used. The rutine 18 mnth dse will be cmpleted with a DTaP-IPV-Hib cntaining vaccine. Children wh have had pertussis infectin shuld cntinue t receive pertussis-cntaining vaccines. Children in whm invasive Hib disease develps befre 24 mnths f age shuld receive Hib vaccine as recmmended because natural disease may nt induce prtectin. Children 7 mnths up t and including 23 mnths f age wh are starting a primary series r wh have an incmplete primary series f INFANRIX hexa shuld cntinue t receive INFANRIX hexa as indicated abve. These children may need fewer dses f the Hib cmpnent; hwever, it is acceptable t give the additinal dses f Hib vaccine in this cmbinatin vaccine fr cnvenience f administratin. Individuals travelling t cuntries currently exprting and/r infected with pli may need special immunizatin dcumentatin verifying pli immunizatin. These individuals shuld cnsult with a Travel Clinic t determine what dcumentatin is required. Immunizatin Prgram Standards Manual Page 2 f 5 Ppulatin, Public and Indigenus Health

Preferred Use Dse Rute Cntraindicatins/ Precautins Pssible Reactins N/A 0.5 ml Nte: Once recnstituted, withdraw the entire cntents f the vial. IM Cntraindicatins: Knwn severe hypersensitivity t any cmpnent f INFANRIX hexa. Anaphylactic reactin t a previus dse f vaccine cntaining diphtheria, tetanus, pertussis, pli, Hib r hepatitis B antigens. Encephalpathy (eg. cma, decreased level f cnsciusness, prlnged seizures) within seven days f a previus dse f a pertussis-cntaining vaccine nt attributable t anther identifiable cause. Precautins: Child Hematpietic Stem Cell Transplant (HSCT) Recipients and Children Pre and Pst Slid Organ Transplant shuld nt receive INFANRIX hexa as INFANRIX hexa cntains a regular strength dse f Hepatitis B vaccine. D nt administer INFANRIX hexa t high risk infants weighing less than 2000g wh received Hepatitis B vaccine and/r HBIG at birth. These infants shuld cntinue t receive the separate Hepatitis B vaccine accrding t the schedule utlined in the Hepatitis B Vaccine Bilgical Page (#07.234). Capsular plysaccharide antigen (Hib antigen) can be detected in the urine f vaccine recipients fr up t tw weeks fllwing immunizatin with cnjugate vaccines. This phenmenn culd be cnfused with antigenuria assciated with invasive Hib infectins. Hib vaccines shuld never be given t a child yunger than six weeks f age. Data suggest that Hib cnjugate vaccines given befre six weeks f age may induce immunlgic tlerance (reduced respnse t subsequent dses). Children with neurlgic cnditins shuld be assessed carefully. If Guillain-Barré Syndrme (GBS) ccurred within eight weeks f immunizatin with a previus dse f vaccine cntaining tetanus txid, it is prudent t withhld subsequent dses f tetanus-cntaining vaccine. Thse wh develp GBS utside f this interval r have an alternative cause identified may receive subsequent dses f tetanus-cntaining vaccine. Cmmn: Apprximately 10% r mre f children receiving INFANRIX hexa will experience pain, redness, swelling at the injectin site, lss f appetite, fatigue, irritability, abnrmal crying, restlessness and fever f 38 C r greater. Apprximately 1-10% f children receiving INFANRIX hexa will experience nervusness, vmiting, diarrhea, lcal swelling at the injectin site (>50 mm), fever >39.5 C (when given at the same time as pneumcccal cnjugate vaccine), pruritus and injectin site reactins, including induratin. Rare: Less than 1% receiving INFANRIX hexa will experience upper respiratry tract infectin, smnlence, swelling f the injected limb, brnchitis, rash, dermatitis. Less than 1% f children receiving INFANRIX hexa will experience brnchspasm, cnvulsin r are at increased risk fr hyptnic hyprespnsive episde when given with pneumcccal cnjugate vaccine Immunizatin Prgram Standards Manual Page 3 f 5 Ppulatin, Public and Indigenus Health

Pregnancy Lactatin Cmpsitin As with any immunizatin, unexpected r unusual side effects can ccur. Refer t the prduct mngraph fr mre detailed infrmatin. Nt intended fr use in adults. Nt intended fr use in adults. Each 0.5 ml dse cntains: Active Ingredients: Diphtheria txid 25 Lf Tetanus txid 10 Lf Acellular pertussis: Pertussis txid (PT) 25 mcg Filamentus haemagglutinin (FHA) 25 mcg Pertactin 8 mcg Hepatitis B 10 mcg Inactivated plimyelitis vaccine Type 1-40 DU Type 2 8 DU Type 3 32 DU Purified plyribsyl-ribitlphsphate capsular plysaccharide (PRP) f Haemphilus influenzae type b cvalently bund t tetanus txid 10 mcg Nn-medical Ingredients: lactse sdium chlride aluminum salts water fr injectin Manufacturing residuals: Frmaldehyde Plysrbate 20 and 80 M199 (as a stabilizer) Ptassium chlride Disdium phsphate Mnptassium phsphate Glycine Nemycin sulphate Plymyxin B sulphate Aluminum phsphate 5% yeast prtein Bld/Bld Des nt cntain human bld r bld prducts. Prducts Bvine/Prcine Des nt cntain bvine r prcine prducts. Prducts Latex Des nt cntain latex. Interchangeability The first three dses f the immunizatin series shuld be cmpleted, whenever pssible, with the same cmbinatin prduct. Hwever, if the riginal vaccine is nt knwn r nt available an alternate cmbinatin prduct may be used t cmplete the primary series, with a separate dse f Hepatitis B vaccine. Either Pediacel r Infanrix -IPV/Hib may be used interchangeably fr the furth dse. Administratin with Other Prducts INFANRIX hexa can be given cncmitantly with pneumcccal cnjugate, MenC cnjugate, MenACWY cnjugate, rtavirus, measles, mumps, rubella Immunizatin Prgram Standards Manual Page 4 f 5 Ppulatin, Public and Indigenus Health

and varicella vaccines. Data have shwn n clinically relevant interference in the antibdy respnse t each f the individual antigens in INFANRIX hexa Can be given at the same time as ther inactivated and live vaccine using a separate needle and syringe fr each vaccine. The same limb may be used if necessary, but different sites n the limb must be chsen Appearance The Hib cmpnent will appear as a lyphilized white pwder. The DTaP-HB-IPV cmpnent is supplied as a turbid white suspensin. The recnstituted vaccine presents as a slightly mre cludy suspensin than the liquid cmpnent alne. Strage Stre at +2 0 C t +8 0 C. D nt freeze. D nt use beynd the labeled expiry date. Stre in riginal packaging when pssible t prtect frm light. Vaccine Cde DTaP-IPV-Hib-HB Antigen Cde Licensed fr Tetanus T Diphtheria D Acellular pertussis P Hepatitis B HB Inactivated pli vaccine POL Haemphilus influenzae type b - Hib Children six weeks up t tw years f age. Ntes: INFANRIX hexa became available September 1, 2016 fr the rutine Alberta Immunizatin Prgram. Related Resurces: Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Pli and Haemphilus influenzae type b Cnjugate Vaccine Infrmatin Sheet (September 1, 2016). References: Alberta Health. (2018, Octber 18). Alberta Immunizatin Plicy. Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Pli-Haemphilus influenzae type b Cnjugate Cmbined Vaccine: INFANRIX hexa. Alberta Health, Health System Accuntability and Perfrmance Divisin. Alberta Health. (2007, Nvember). Public Health and Cmpliance Divisin Alberta Immunizatin Plicy Adverse Events. Fllwing Immunizatin Interpretatin f DAT and TAT Levels. GlaxSmithKline. (2016, April 25). Prduct Mngraph. INFANRIX hexa : Cmbined diphtheria and tetanus txids, acellular pertussis, hepatitis B (recmbinant), inactivated plimyelitis and adsrbed cnjugated Haemphilus influenzae type b vaccine. Natinal Advisry Cmmittee n Immunizatin. (2017). Canadian Immunizatin Guide (Evergreen Editin). Ottawa, ON: Public Health Agency f Canada. Immunizatin Prgram Standards Manual Page 5 f 5 Ppulatin, Public and Indigenus Health